Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma

BACKGROUND: While cancer immunotherapies including checkpoint blockade antibodies, adoptive T cell therapy, and even some vaccines have given rise to major clinical responses with durability in many cases, a subset of patients who initially respond subsequently develop secondary resistance to therap...

Full description

Bibliographic Details
Main Authors: Trujillo, Jonathan A, Luke, Jason J, Zha, Yuanyuan, Segal, Jeremy P, Ritterhouse, Lauren L, Spranger-Zimmermann, Stefani, Matijevich, Karen, Gajewski, Thomas F
Other Authors: Koch Institute for Integrative Cancer Research at MIT
Format: Article
Language:English
Published: BioMed Central 2020
Online Access:https://hdl.handle.net/1721.1/126359

Internet

https://hdl.handle.net/1721.1/126359

Similar Items